AstraZeneca (AZN)
(Delayed Data from NSDQ)
$78.58 USD
+0.05 (0.06%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $78.59 +0.01 (0.01%) 6:06 PM ET
3-Hold of 5 3
B Value D Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AZN 78.58 +0.05(0.06%)
Will AZN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AZN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AZN
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
AZN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering
Relay Stock Soars on Upbeat Data From Breast Cancer Study
GSK's Respiratory Drug Nucala Meets Goal in COPD Study
Other News for AZN
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
AstraZeneca: A Buy Rating Based on Promising Pipeline and Regulatory Prospects
ESMO 2024 Roundup: A Lot Of Stumbles, But There Are New Signs Of Life
LONDON MARKET MIDDAY: Glum trade for FTSE 100 before Fed decides
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis